Condensed Consolidated Statements of Income (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenue
Blood services	$ 1,968,000	$ 1,931,000	$ 3,728,000	$ 3,835,000
Therapeutic services	2,270,000	1,947,000	4,418,000	3,724,000
Total revenue	4,238,000	3,878,000	8,146,000	7,559,000
Operating costs and expenses
Blood services	2,113,000	1,949,000	3,860,000	3,716,000
Therapeutic services	1,542,000	1,408,000	3,005,000	2,740,000
Total operating costs and expenses	3,655,000	3,357,000	6,865,000	6,456,000
Gross profit	583,000	521,000	1,281,000	1,103,000
General and administrative expenses	1,212,000	1,131,000	2,395,000	2,668,000
Loss from operations	(629,000)	(610,000)	(1,114,000)	(1,565,000)
Gain from disposal of assets	197,000		197,000
Loss from continuing operations	(432,000)	(610,000)	(917,000)	(1,565,000)
Provision for income taxes		10,000	10,000	10,000
Loss from continuing operations, net of tax	(432,000)	(620,000)	(927,000)	(1,575,000)
Income from discontinued operations, net of tax	180,000	843,000	285,000	1,595,000
Net (loss) income	$ (252,000)	$ 223,000	$ (642,000)	$ 20,000
Basic
Continuing operations (in Dollars per share)	$ (0.04)	$ (0.06)	$ (0.10)	$ (0.16)
Discontinued operations (in Dollars per share)	$ 0.02	$ 0.08	$ 0.03	$ 0.16
Total (in Dollars per share)	$ (0.03)	$ 0.02	$ (0.07)	$ 0.00
Diluted
Continuing operations (in Dollars per share)	$ (0.04)	$ (0.06)	$ (0.10)	$ (0.15)
Discontinued operations (in Dollars per share)	$ 0.02	$ 0.08	$ 0.03	$ 0.16
Total (in Dollars per share)	$ (0.03)	$ 0.02	$ (0.07)	$ 0.00
Weighted average shares outstanding-basic (in Shares)	9,712,948	10,049,148	9,712,948	10,049,339
Weighted average shares outstanding-diluted (in Shares)	9,712,948	10,234,148	9,712,948	10,232,339